OMERS ADMINISTRATION Corp Decreases Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

OMERS ADMINISTRATION Corp decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 50.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,800 shares of the company's stock after selling 50,800 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Roivant Sciences were worth $601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of ROIV. Russell Investments Group Ltd. lifted its holdings in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after acquiring an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Roivant Sciences in the 4th quarter worth $39,000. PNC Financial Services Group Inc. lifted its stake in Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Roivant Sciences by 84.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after purchasing an additional 3,426 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after buying an additional 6,667 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 434,478 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the transaction, the chief operating officer now directly owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. This represents a 27.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,223,959 shares of company stock worth $13,420,035. Company insiders own 7.90% of the company's stock.

Roivant Sciences Stock Up 0.3%

Shares of Roivant Sciences stock opened at $10.79 on Monday. The company's fifty day simple moving average is $10.51 and its two-hundred day simple moving average is $11.07. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06. The firm has a market cap of $7.70 billion, a PE ratio of -71.93 and a beta of 1.23.

Analysts Set New Price Targets

Several research firms have recently commented on ROIV. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.